{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:54:57Z","timestamp":1791345297655,"version":"4.3.1"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013100","name":"Scientific Research Funds of Jilin Province of Health and Family Planning Commission","doi-asserted-by":"publisher","award":["2016Q036"],"award-info":[{"award-number":["2016Q036"]}],"id":[{"id":"10.13039\/501100013100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81501089"],"award-info":[{"award-number":["81501089"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31600820"],"award-info":[{"award-number":["31600820"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["20180520110JH"],"award-info":[{"award-number":["20180520110JH"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.msard.2018.09.040","type":"journal-article","created":{"date-parts":[[2018,10,2]],"date-time":"2018-10-02T18:51:34Z","timestamp":1538506294000},"page":"34-41","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Resolution of inflammation in neuromyelitis optica spectrum disorders"],"prefix":"10.1016","volume":"27","author":[{"given":"Xu","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuzhe","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiachun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.09.040_bib0002","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11910-008-0066-2","article-title":"Neuromyelitis optica: Diagnosis, pathogenesis, and treatment","volume":"8","author":"Cree","year":"2008","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2018.09.040_bib0003","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1073\/pnas.1209362110","article-title":"Identification of an essential endogenous regulator of blood-brain barrier integrity, and its pathological and therapeutic implications","volume":"110","author":"Cristante","year":"2013","journal-title":"PNAS"},{"key":"10.1016\/j.msard.2018.09.040_bib0004","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.23648","article-title":"The blood-brain barrier in health and disease","volume":"72","author":"Daneman","year":"2012","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2018.09.040_bib0005","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jneuroim.2011.01.007","article-title":"Temporal dynamics of cerebrospinal fluid anti-aquaporin-4 antibodies in patients with neuromyelitis optica spectrum disorders","volume":"234","author":"Dujmovic","year":"2011","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2018.09.040_bib0006","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S1567-5769(03)00133-4","article-title":"Anti-inflammatory effects of annexin-1: stimulation of IL-10 release and inhibition of nitric oxide synthesis","volume":"3","author":"Ferlazzo","year":"2003","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.msard.2018.09.040_bib0007","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.smim.2015.03.014","article-title":"The resolution of inflammation: principles and challenges","volume":"27","author":"Headland","year":"2015","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.msard.2018.09.040_bib0008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00207450903428970","article-title":"Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients","volume":"120","author":"Icoz","year":"2010","journal-title":"Int. J. Neurosci."},{"key":"10.1016\/j.msard.2018.09.040_bib0009","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1742-2094-7-52","article-title":"Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance","volume":"7","author":"Jarius","year":"2010","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2018.09.040_bib0010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jns.2010.01.002","article-title":"Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen","volume":"291","author":"Jarius","year":"2010","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2018.09.040_bib0011","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.bbrc.2009.06.085","article-title":"Neuromyelitis optica: passive transfer to rats by human immunoglobulin","volume":"386","author":"Kinoshita","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.msard.2018.09.040_bib0012","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbrc.2010.02.157","article-title":"Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells","volume":"394","author":"Kinoshita","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.msard.2018.09.040_bib0013","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1212\/01.wnl.0000345066.57745.50","article-title":"NMO-IgG detected in CSF in seronegative neuromyelitis optica","volume":"72","author":"Klawiter","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.040_bib0014","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.040_bib0015","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2018.09.040_bib0016","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10875-012-9780-2","article-title":"The ex vivo production of IL-6 and IL-21 by CD4+ T cells is directly associated with neurological disability in neuromyelitis optica patients","volume":"33","author":"Linhares","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.msard.2018.09.040_bib0017","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1161\/ATVBAHA.112.249508","article-title":"Resolvin D1 limits PMN recruitment to inflammatory loci: receptor dependent actions","volume":"32","author":"Norling","year":"2012","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.msard.2018.09.040_bib0018","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nri2470","article-title":"Annexin A1 and glucocorticoids as effectors of the resolution of inflammation","volume":"9","author":"Perretti","year":"2009","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.msard.2018.09.040_bib0019","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2018.09.040_bib0020","doi-asserted-by":"crossref","first-page":"11981","DOI":"10.1073\/pnas.95.20.11981","article-title":"Direct immunogold labeling of aquaporin-4 in square arrays of astrocyte and ependymocyte plasma membranes in rat brain and spinal cord","volume":"95","author":"Rash","year":"1998","journal-title":"PNAS"},{"key":"10.1016\/j.msard.2018.09.040_bib0021","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/brain\/awp309","article-title":"Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice","volume":"133","author":"Saadoun","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.msard.2018.09.040_bib0022","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.atc.2006.01.003","article-title":"Novel chemical mediators in the resolution of inflammation: resolvins and protectins","volume":"24","author":"Serhan","year":"2006","journal-title":"Anesthesiology Clin."},{"key":"10.1016\/j.msard.2018.09.040_bib0023","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature13479","article-title":"Novel pro-resolving lipid mediators in inflammation are leads for resolution physiology","volume":"510","author":"Serhan","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.msard.2018.09.040_bib0024","doi-asserted-by":"crossref","first-page":"5922","DOI":"10.1021\/cr100396c","article-title":"Resolvins and protectins in inflammation-resolution","volume":"111","author":"Serhan","year":"2011","journal-title":"Chem. Rev."},{"key":"10.1016\/j.msard.2018.09.040_bib0025","doi-asserted-by":"crossref","first-page":"618","DOI":"10.2337\/db12-0684","article-title":"Proresolution therapy for the treatment of delayed healing of diabetic wounds","volume":"62","author":"Tang","year":"2013","journal-title":"Diabetes"},{"key":"10.1016\/j.msard.2018.09.040_bib0026","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1177\/147323001204000427","article-title":"Blood\u2014brain barrier disruption is more severe in neuromyelitis optica than in multiple sclerosis and correlates with clinical disability","volume":"40","author":"Tomizawa","year":"2012","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.msard.2018.09.040_bib0027","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1177\/1352458510379247","article-title":"Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6","volume":"16","author":"Uzawa","year":"2010","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2018.09.040_bib0028","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bpa.12097","article-title":"Cytokines and chemokines in neuromyelitis optica: pathogenetic and therapeutic implications","volume":"24","author":"Uzawa","year":"2014","journal-title":"Brain Pathol."},{"key":"10.1016\/j.msard.2018.09.040_bib0029","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1007\/s10875-012-9837-2","article-title":"Increased plasma interleukin-32 expression in patients with neuromyelitis optica","volume":"33","author":"Wang","year":"2013","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.msard.2018.09.040_bib0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000345994","article-title":"Cerebrospinal fluid high-mobility group box protein 1 in neuromyelitis optica and multiple sclerosis","volume":"20","author":"Wang","year":"2013","journal-title":"Neuroimmunomodulation"},{"key":"10.1016\/j.msard.2018.09.040_bib0031","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1089\/jir.2012.0040","article-title":"Distinct serum cytokine profiles in neuromyelitis optica and multiple sclerosis","volume":"33","author":"Wang","year":"2013","journal-title":"J. Interferon Cytokine Res."},{"key":"10.1016\/j.msard.2018.09.040_bib0032","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1177\/0271678X16669513","article-title":"Identification of two phosphorylation sites essential for annexin A1 in blood-brain barrier protection after experimental intracerebral hemorrhage in rats","volume":"37","author":"Wang","year":"2017","journal-title":"J. Cereb. Blood Flow Metab."},{"key":"10.1016\/j.msard.2018.09.040_bib0033","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.040_bib0034","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.040_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2018.09.040_bib0036","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2018.09.040_bib0037","doi-asserted-by":"crossref","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.09.040_bib0038","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jneuroim.2011.10.001","article-title":"Cerebrospinal fluid levels of CXCL13 are elevated in neuromyelitis optica","volume":"240-241","author":"Zhong","year":"2011","journal-title":"J. Neuroimmunol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818303602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:48Z","timestamp":1761900348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818303602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":37,"alternative-id":["S2211034818303602"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.040","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolution of inflammation in neuromyelitis optica spectrum disorders","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}